Terms: = Ovarian cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Diagnosis
41 results:
1. Association between inflammatory bowel disease and cancer risk: evidence triangulation from genetic correlation, Mendelian randomization, and colocalization analyses across East Asian and European populations.
Liu D; Cao M; Wang H; Cao W; Zheng C; Li Y; Wang Y
BMC Med; 2024 Mar; 22(1):137. PubMed ID: 38528540
[TBL] [Abstract] [Full Text] [Related]
2. Linear IgA bullous dermatosis associated with immunotherapy.
Momin B; Nguyen TF; Glade D; Messer A
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478666
[TBL] [Abstract] [Full Text] [Related]
3. CD133, CD47, and PD-L1 Expression in ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.
Masadah R; Ikram D; Riadi R; Tangdiung Y; Nelwan BJ; Ghaznawie M; Rauf S; Faruk M
Asian Pac J Cancer Prev; 2024 Jan; 25(1):249-255. PubMed ID: 38285791
[TBL] [Abstract] [Full Text] [Related]
4. ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of ovarian cancer Screening (UKCTOCS).
Dilley J; Gentry-Maharaj A; Ryan A; Burnell M; Manchanda R; Kalsi J; Singh N; Woolas R; Sharma A; Williamson K; Mould T; Fallowfield L; Campbell S; Skates SJ; McGuire A; Parmar M; Jacobs I; Menon U
Gynecol Oncol; 2023 Dec; 179():123-130. PubMed ID: 37980767
[TBL] [Abstract] [Full Text] [Related]
5. Application of Immune Checkpoint Inhibitors in Gynecological cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract] [Full Text] [Related]
6. Duplex-immunoassay of ovarian cancer biomarker CA125 and HE4 based carbon dot decorated dendritic mesoporous silica nanoparticles.
Wang ZX; Ding SN
Analyst; 2023 Jan; 148(3):683-689. PubMed ID: 36629898
[TBL] [Abstract] [Full Text] [Related]
7. Primary leiomyosarcoma of ovary: A rare malignancy as an incidental finding.
Raychaudhuri S; Sidam D; Jain M; Chawla R; Pujani M; Wadhwa R
Indian J Pathol Microbiol; 2022; 65(4):938-941. PubMed ID: 36308213
[TBL] [Abstract] [Full Text] [Related]
8. [Preliminary study on the diagnostic value of serum-derived exosomal lncRNA in epithelial ovarian cancer].
Li YW; Li L
Zhonghua Fu Chan Ke Za Zhi; 2022 Mar; 57(3):198-209. PubMed ID: 35385957
[No Abstract] [Full Text] [Related]
9. Targeted design of green carbon dot-CA-125 aptamer conjugate for the fluorescence imaging of ovarian cancer cell.
Heidari F; Mohajeri N; Zarghami N
Cell Biochem Biophys; 2022 Mar; 80(1):75-88. PubMed ID: 34716880
[TBL] [Abstract] [Full Text] [Related]
10. Gene expression in the Angiopoietin/TIE axis is altered in peripheral tissue of ovarian cancer patients: A prospective observational study.
Kinnen A; Klaschik S; Neumann C; Egger EK; Mustea A; Soehle M; Frede S; Velten M; Coburn M; Hilbert T
Life Sci; 2021 Jun; 274():119345. PubMed ID: 33713666
[TBL] [Abstract] [Full Text] [Related]
11. Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Sakamoto T; Kakimoto S; Iwahashi H; Tsuda H; Takano M
J Ovarian Res; 2021 Feb; 14(1):33. PubMed ID: 33583413
[TBL] [Abstract] [Full Text] [Related]
12. A Rare Case of Castleman Disease Presenting as an ovarian Tumor.
D'Antonio A; Caleo A; Addesso M; Caputo A; Fraggetta F; Ponzoni M
Int J Gynecol Pathol; 2021 Jul; 40(4):379-382. PubMed ID: 33323851
[TBL] [Abstract] [Full Text] [Related]
13. Tubal ligation during cesarean delivery and future risk for ovarian cancer: a population-based cohort study.
Kessous R; Sergienko R; Sheiner E
Arch Gynecol Obstet; 2020 Jun; 301(6):1473-1477. PubMed ID: 32322983
[TBL] [Abstract] [Full Text] [Related]
14. Immune checkpoint inhibitors of ctla4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
Yano M; Asami Y; Nishikawa T; Yoshida S; Kamada K; Katoh T; Teramoto Y; Nakamura Y; Yasuda M
Medicine (Baltimore); 2018 Oct; 97(43):e12937. PubMed ID: 30412106
[TBL] [Abstract] [Full Text] [Related]
15. diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in ovarian cancer: A Series of Case Vignettes.
Johnson C; Jazaeri AA
Clin Ther; 2018 Mar; 40(3):389-394. PubMed ID: 29519715
[TBL] [Abstract] [Full Text] [Related]
16. An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing.
Hamd-Ghadareh S; Salimi A; Fathi F; Bahrami S
Biosens Bioelectron; 2017 Oct; 96():308-316. PubMed ID: 28525848
[TBL] [Abstract] [Full Text] [Related]
17. The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial ovarian cancer: A Brief Report.
Cannioto RA; Sucheston-Campbell LE; Hampras S; Goode EL; Knutson K; Ness R; Modugno F; Wallace P; Szender JB; Mayor P; Hong CC; Joseph JM; Friel G; Davis W; Nesline M; Eng KH; Edwards RP; Kruszka B; Schmitt K; Odunsi K; Moysich KB
Int J Gynecol Cancer; 2017 Jan; 27(1):11-16. PubMed ID: 27759594
[TBL] [Abstract] [Full Text] [Related]
18. Characteristics of human amniotic fluid mesenchymal stem cells and their tropism to human ovarian cancer.
Li L; Wang D; Zhou J; Cheng Y; Liang T; Zhang G
PLoS One; 2015; 10(4):e0123350. PubMed ID: 25880317
[TBL] [Abstract] [Full Text] [Related]
19. Antibody-based immunotherapy for ovarian cancer: where are we at?
Tse BW; Collins A; Oehler MK; Zippelius A; Heinzelmann-Schwarz VA
Ann Oncol; 2014 Feb; 25(2):322-31. PubMed ID: 24285017
[TBL] [Abstract] [Full Text] [Related]
20. [Bilateral metastases of renal cell carcinoma to the ovaries--a case report].
Hołody-Zareba J; Kinalski P; Sulkowski S; Kozłowski R; Kinalski M
Ginekol Pol; 2013 Jul; 84(7):650-3. PubMed ID: 24032280
[TBL] [Abstract] [Full Text] [Related]
[Next]
